Opinion|Videos|January 20, 2025
Impact of Tardive Dyskinesia on Quality of Life
Panelists discuss how untreated tardive dyskinesia severely impacts patients' daily functioning and quality of life through physical limitations affecting basic tasks like eating and walking, social isolation due to visible symptoms, and heightened risks for older adults who face increased fall risks, difficulty maintaining independence, and complications from age-related comorbidities.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- How does untreated TD impact patients’ overall health, activities of daily living, and quality of life.
- What unique challenges do older adult patients with TD face?
Advertisement
Related to this article
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
No new vouchers have been awarded since former FDA Commissioner Marty Makary left the agency in May, though HHS maintains the pilot is ongoing.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Nicole Albanese, PharmD, explains how a structured testing schedule and simple notes help patients bring useful glucose data to their care team.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
2
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
3
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5